43rd week of 2010 patent applcation highlights part 46 |
Patent application number | Title | Published |
20100273741 | Apparatus and Methods for Adipose Tissue Detection - The present invention finds application in the field of cosmetic medicine and particularly relates to an apparatus for adipose tissue detection which comprises a first electronic circuit for generating a beam of electromagnetic waves, radiating means for orienting the beam to an adipose tissue-containing part, sensor means for detecting reflected waves, a second electronic circuit for receiving the reflected electromagnetic waves, a unit for measuring a predetermined characteristic of the reflected waves and for producing an analog signal, a third electronic circuit for converting the analog signal into a digital signal, interface means providing an interface between the third electronic circuit and a graphic processing unit. The first electronic circuit comprises means for modulating the frequency of the generated waves, which operate in a microwave range from 1 GHz to 12 GHz. | 2010-10-28 |
20100273742 | Pharmacologically Active Agents Containing Esterified Phosphonates and Methods for Use Thereof - Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections, cell proliferation and bone metabolism. The compounds provided herein are alkyl esters of phosphonates. | 2010-10-28 |
20100273743 | MORPHOLIN-4-IUM 4 METHOXYPHENYL (MORPHOLINO) PHOSPHINODITHIOATE (GYY4137) AS A NOVEL VASODILATOR AGENT - The invention is directed to a method of administering hydrogen sulfide (H | 2010-10-28 |
20100273744 | COMPOUNDS - The present invention relates to amide compounds, processes for their preparation, pharmaceutical compositions containing these compounds and to their use in the treatment of disorders, conditions or disorders such as allergic disorders, inflammatory disorders and disorders of the immune system. | 2010-10-28 |
20100273745 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS - Polyamine, polyamine/guanidino, and polyamine/biguanide compounds are disclosed. The compounds are useful as anti-cancer and anti-parasitic treatments. The compounds are also useful as inhibitors of the enzyme lysine-specific demethylase-1. | 2010-10-28 |
20100273746 | PHARMACEUTICAL FORMULATIONS CONTAINING TOLPERISONE - The present invention relates to pharmaceutical formulation containing tolperisone or its pharmaceutically acceptable salts or tolperisone combined with a non-steroidal anti-inflammatory drug or their salts, gel forming macromolecule, solvent, and if required thickening agent, penetration enhancer and pH adjuvant or the mixture thereof. The invention also relates to the manufacturing process of the above mentioned pharmaceutical compositions, further the use of these formulations and the containers suitable for the dosage, which are dual compartment containers consisting of two separated chambers. | 2010-10-28 |
20100273747 | Freeze-Dried Composition of Active Substances - The invention relates to freeze-dried molded articles, containing ≧50% by wt. of one or more active substances, and >15% by wt. of one or more scaffold-forming agents, with proteins being excepted, as well as optionally one or more auxiliary substances, in each case based on the total composition of the freeze-dried molded article, whose 1% by wt. solution or suspension in water, at 20° C., has a pH value <7. Furthermore, the invention relates to methods for manufacturing these freeze-dried molded articles, the combination of such freeze-dried molded articles in kit-of-parts arrangements together with aqueous solutions, as well as the use of the freeze-dried molded articles and the kit-of-parts combinations for pharmaceutical and cosmetic application. | 2010-10-28 |
20100273748 | ANTIMICROBIAL THERAPY - Methods and compositions for modulating gene expression and the innate immune response by 1,25(OH) | 2010-10-28 |
20100273749 | Method for Treating Dry-Eye Syndrome - The subject application provides an aqueous composition suitable for use as an artificial tear solution comprising one or more lipids produced by an enzyme of the diacylglycerol acyltransferase 2 (DGAT2) family and/or the acyl-CoA cholesterol acytransferase (ACAT) family. This invention also provides related methods. | 2010-10-28 |
20100273750 | SEROTONIN RECEPTOR ANTAGONISTS FOR TREATING ARTHRITIS - The present invention relates to serotonin receptor antagonists for treating inflammatory arthritis and related conditions. The present invention also relates to a kit comprising a pharmaceutical composition comprising a serotonin receptor antagonist and instructions indicating that the composition is for use in treating inflammatory arthritis and related conditions. In addition, the present invention relates to a method of treating inflammatory arthritis and related conditions comprising administration of a serotonin receptor antagonist. The method is preferably carried out on a subject in need of treatment. The inflammatory arthritis is preferably rheumatoid arthritis. | 2010-10-28 |
20100273751 | SUBSTITUTED BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - This invention relates to certain biologically active chemical compounds, namely benzoimidazolyl-pyrazine derivatives or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders. | 2010-10-28 |
20100273752 | MEQUITAZINE FOR TREATING OR PREVENTING PATHOLOGIES INVOLVING HISTAMINE H4 RECEPTORS - The present application relates to the use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine, 10-[(3S)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine or 10-[(3R,3S)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine, or a pharmaceutically acceptable salt thereof, to prepare a drug to prevent or treat pathologies involving histamine H4 receptor. | 2010-10-28 |
20100273753 | ORGANIC COMPOUNDS - 1- or 2- or 7-(substituted)-3-(optionally hetero)arylamino-[1H, 2H]-pyrazolo[3,4-d] pyrimidine-4,6(5H, 7H)-dione derivatives, in free, salt or prodrug form, are useful as pharmaceuticals, particularly as phosphodiesterase 1 inhibitors, useful treatment of diseases involving disorders of the dopamine D1 receptor intracellular pathway, such as Parkinson's disease, depression, narcolepsy and damage to cognitive function, e.g., in schizophrenia or disorders that may be ameliorated through enhanced progesterone-signaling pathway, e.g., female sexual dysfunction. | 2010-10-28 |
20100273754 | ORGANIC COMPOUNDS - 1- or 2-substituted (6aR,9aS)-3-(phenylamino)-5-6a,7,8,9,9a-hexahydro-5-methyl-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(1H or, 2H)-one compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them. | 2010-10-28 |
20100273755 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY - This invention relates to a compound of formula I: | 2010-10-28 |
20100273756 | ADJUNCTIVE FORMULATION AND METHODS FOR PALLIATION OF FINE WRINKLES, MOTTLED HYPERPIGMENTATION, TACTILE ROUGHNESS OF FACIAL SKIN AND RELATED DISORDERS - The present invention is generally directed to the treatment of fine wrinkles, hyperpigmentation, roughness of facial skin, improvement of photoaging, repair of sun damaged skin, and related disorders. In a formulation aspect, the present invention provides a formulation for the adjunct treatment of skin disorders, where the formulation includes tretinoin and azelaic acid. In a method aspect, the present invention provides a method for treating skin disorders. The skin disorders include fine wrinkles, freckles, solar lentigo, skin photodamage, aging process as reflected by changes in a patient's skin, Acne Vulgaris and Melasma or Post-inflammatory hyperpigmentation. The method includes the application of a formulation to a portion of the patient's skin, where the portion exhibits a skin disorder, and wherein the formulation includes tretinoin and azelaic acid. | 2010-10-28 |
20100273757 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS - The present invention provides a compound of formula (I) wherein: A represents an optionally substituted monocyclic or polycyclic aryl or heteroaryl group B represents an optionally substituted monocyclic nitrogen-containing heteroaryl group; and either a) R | 2010-10-28 |
20100273758 | Sulfonamide Derivatives For The Treatment Of Diseases - The invention relates to compounds of formula (1) | 2010-10-28 |
20100273759 | PROGESTERONE ANTAGONISTS - Described herein are compounds which exhibit progesterone antagonistic effects and methods of treating cancer using such compounds. | 2010-10-28 |
20100273760 | Topical Pharmaceutical Formulations And Methods Of Treatment - In certain embodiments, the present invention is directed to a pharmaceutical formulation for topical administration on a mammal, comprising a unit dose of a therapeutically effective amount of a therapeutic agent and a pharmaceutically acceptable carrier medium therefor, said formulation being solid at ambient temperature and having a softening point of not higher than 35° C., such that when the formulation is placed in continuous contact with the skin of a mammalian patient, it is softened to a consistency to effect substantial application of the unit dose of said therapeutic agent onto a desired skin area of the mammalian patient within a time period of less than 10 minutes. | 2010-10-28 |
20100273761 | NUCLEAR SULFATED OXYSTEROL, POTENT REGULATOR OF LIPID HOMEOSTASIS, FOR THERAPY OF HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDES, FATTY LIVER DISEASES, AND ATHEROSCLEROSIS - The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided. | 2010-10-28 |
20100273762 | Method of combating infection - A method of combating a parasitic protozoal infection of a host organism, the method comprising administering tretazicar to the host organism. Tretazicar is the compound 5-(aziridin- | 2010-10-28 |
20100273763 | ORGANOMETALLIC COMPLEXES AS THERAPEUTIC AGENTS - This invention comprises salophene-based metallic complexes. Included are metal-chelating analogues, and method of their preparation and use. These analogues have therapeutic activity including anticancer activity. | 2010-10-28 |
20100273764 | INHIBITORS OF PI3 KINASE AND/OR MTOR - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; | 2010-10-28 |
20100273765 | Rifamycin analogs and uses thereof - The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3′-hydroxy analogs, 4′- and/or 6′ halo and/or alkoxy analogs, and various 5′ substituents that incorporate a cyclic amine moiety. | 2010-10-28 |
20100273766 | SUBSTITUTED OXINDOL DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF - The invention relates to novel oxindole derivatives of general formula (I), wherein the substituents R | 2010-10-28 |
20100273767 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF - The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2 -a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7 -octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2 -a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) | 2010-10-28 |
20100273768 | Inhibitors of Bruton's Tyrosine Kinase - This application discloses 5-phenyl-1H-pyridin-2-one, 6-phenyl-2H-pyridazin-3-one, and 5-phenyl-1H-pyrazin-2-one derivatives according to generic Formulae I-II: | 2010-10-28 |
20100273769 | COMPOSITION AND METHOD FOR THE TREATMENT OF PARKINSON'S DISEASE - The present invention relates to the use of specific indolocarbazole compounds for the preparation of pharmaceutical compositions for the treatment of Parkinson's disease. In particular, the compounds of the invention are useful for the prevention or treatment of PD, similar forms of Parkinsonism, and synucleopathies involving Lewy body neurodegeneration. | 2010-10-28 |
20100273770 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES - The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders. | 2010-10-28 |
20100273771 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) - The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders. | 2010-10-28 |
20100273772 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) - Disclosed are compounds of Formula I: | 2010-10-28 |
20100273773 | DIBENZOAZEPINE AND DIBENZOOXAZEPINE TRPA1 AGONISTS - The present invention is related to novel tricyclic compounds of formula (I) having TRPA1 receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use as pharmacological tools, or as irritant incapacitants, or in the treatment of diseases linked to the modulation of the TRPA1 receptors in animals, in particular humans. | 2010-10-28 |
20100273774 | INDOLYMALEIMIDE DERIVATIVES - A compound of formula (I), wherein R, R | 2010-10-28 |
20100273775 | FUNGICIDAL BICYCLIC PYRAZOLES - Disclosed are compounds of Formulae 1 and 1a, N-oxides, and salts thereof, | 2010-10-28 |
20100273776 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY - Compounds and compositions are provided for treatment or amelioration of one or more symptoms of α-synuclein toxicity, α-synuclein mediated diseases or diseases in which α-synuclein fibrils are a symptom or cause of the disease. | 2010-10-28 |
20100273777 | Compounds for Modulating TRPV3 Function - The present application relates to compounds and methods for treating pain and other conditions related to TRPV3. | 2010-10-28 |
20100273778 | TREATMENT OF OSTEOARTHRITIS PAIN - This invention discloses a method of treatment of osteoarthritis pain by administration of a histamine H | 2010-10-28 |
20100273779 | Pyridazinone Derivatives - The present invention is directed to novel pyridizinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition. | 2010-10-28 |
20100273780 | SUBSTITUTED 8-HETEROARYL XANTHINES - The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A | 2010-10-28 |
20100273781 | CXCR3 RECEPTOR ANTAGONISTS - The present invention relates to compounds of formula (I): | 2010-10-28 |
20100273782 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS - Provided herein are 2,5-disubstituted arylsulfonamides that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition. | 2010-10-28 |
20100273783 | Compositions and Methods for Treating and Preventing Overactive Bladder and Conditions Associated Therewith - Compositions and methods for the treatment and prevention of overactive bladder are provided. Such compositions and methods provide locally effective amounts of diazepam sufficient to treat or prevent overactive bladder and conditions associated therewith. | 2010-10-28 |
20100273784 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS - Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions. | 2010-10-28 |
20100273785 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS - Provided herein are 2,5-disubstituted arylsulfonamide CCR3 antagonists of Formula I or II, and pharmaceutical compositions thereof: | 2010-10-28 |
20100273786 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF - Tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I), their preparation methods, pharmaceutical compositions containing the derivatives and uses thereof as medicaments, especially as dipeptidyl peptidase IV inhibitors, wherein the substituents of formula (I) are defined as same as the description. | 2010-10-28 |
20100273787 | KYNURENINE-AMINOTRANSFERASE INHIBITORS - Compounds of formula (I): prodrug derivatives and/or pharmaceutically acceptable salt thereof, selectively inhibit the enzyme kynurenine aminotransferase, thereby reducing the synthesis of kynurenic acid. The compounds are used for the treatment of psychiatric and neurological diseases which benefit from an increase in glutamatergic and/or cholinergic neurotransmission, such as schizophrenia, depression, bipolar illness, anxiety and Alzheimer's disease. Furthermore, the compounds of the invention are useful for stimulating attention, memory and other cognitive processes in normal individuals of any age, including children, adolescents and the elderly. Additionally, the compounds of the invention are also useful for treatment of patients suffering from malaria by preventing parasite gametogenesis and fertility based on reduction of xanthurenic acid formation from its bioprecursor 3-hydroxy kynurenine. | 2010-10-28 |
20100273788 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF - The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. | 2010-10-28 |
20100273789 | AMINOACYL PRODRUGS - The present application relates to prodrug derivatives of 5-chloro-N-({(5S)-2-oxo-3-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of thromboembolic disorders. | 2010-10-28 |
20100273790 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF - This invention provides a process for the preparation of S-Rivaroxaban and/or R-Rivaroxaban comprising reacting, in the presence of a first base, a compound of Formula 9: | 2010-10-28 |
20100273791 | TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS - The present invention relates to novel compounds of general formula (I), | 2010-10-28 |
20100273792 | MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS - The present invention relates to inhibitors of HCV replication of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, | 2010-10-28 |
20100273793 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS - The disclosure relates to compounds of formula (I): | 2010-10-28 |
20100273794 | Benzimidazolone Compounds Having 5-HT4 Receptor Agonistic Activity - This invention provides a compound of the formula (I): | 2010-10-28 |
20100273795 | ARYLSULFONAMIDE CCR3 ANTAGONISTS - Provided herein are arylsulfonamides that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition. | 2010-10-28 |
20100273796 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS - Compounds of the formula I | 2010-10-28 |
20100273797 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF - The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions medicated by cytokines such as arthritis. | 2010-10-28 |
20100273798 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF - This invention provides a process for the preparation of S-Rivaroxaban and/or R-Rivaroxaban comprising reacting, in the presence of a first base, a compound of Formula 9: | 2010-10-28 |
20100273799 | SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF - The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s). | 2010-10-28 |
20100273800 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE - This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly Cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly Cancer. | 2010-10-28 |
20100273801 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS - The invention relates to compouns derived from betulin, and to the use thereof as antibacterial agents in pharmaceutical and cosmetic applications. | 2010-10-28 |
20100273802 | NEW PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTI-PROLIFERATIVE PROPERTIES, AND THEIR BIOLOGICAL USES - This invention provides 2-, 6, and 9-substituted purine derivatives, particularly 2(1-R hydroxymethylpropylamino)-6-benzylamino-9-isopropyl purine, having, in particular, antiproliferative properties, and suitable for use as pharmaceutical compositions and herbicidal compositions. Also provided are pharmaceutical compositions and herbicidal compositions comprising the 2-, 6, and 9-substituted purine derivatives, and methods of treatment using the 2-, 6, and 9-substituted purine derivatives. | 2010-10-28 |
20100273803 | Oral Formulations for Tetrapyrrole Derivatives - Oral formulations and method of formulating photosensitive agents for oral administration during photodynamic therapy (PDT) and Antimicrobial photodynamic therapy (APDT) treatment are presented. The oral formulated photosensitizers show increased solubility and permeability, thus improving the bioavailability of photosensitizers at the treatment site. An orally administered photosensitizer is suitably formulated for mucosal adhesion and absorption via gastrointestinal mucosal membranes. Oral formulation provided herein use lipids and known proteins as carriers for photosensitizers by oral route. Carriers for encapsulating preselected photosensitizers include conventional liposomes, pegylated liposomes, nanoemulsions, nanocrystrals, nanoparticles, fatty emulsions, lipidic formulations, hydrosols, SMEDDS, Alpha-Feto protein (AFP), and Bovine-Serum-Albumin (BSA), fatty emulsions, hot-melt-extrudates and nanoparticles. The oral formulation, in case of a hydrophobic photosensitizer in the present invention, is stabilized using suitable surfactants/solubilizers thus preventing aggregation of the drug in the stomach and until it is absorbed in the duodenum and the small intestine. Oral formulations can be administered in the form of liquid, capsule, tablet, powder, paste or gel. Formulated drugs can be administered orally as one single dose or in multiple doses before administering PDT. In one embodiment Temoporfin (m-THPC) is used as a photosensitizer in the oral formulations. Temoporfin like many hydrophobic photosensitizers are especially suitable to be administered orally because there is no known enzyme system in the mammalian body which can metabolize Temoporfin or similar photosensitizers. Temoporfin can reach the blood system unchanged and fully active after absorption of the formulation in the gastrointestinal tract. | 2010-10-28 |
20100273804 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER - The present invention relates to novel pyridazine derivatives of formula (I) as active ingredients which have microbiocidal activity, in particular fungicidal activity: formula (I) wherein R | 2010-10-28 |
20100273805 | SULPHIDE BRIDGED DERIVATIVES AS MODULATORS OF MGLUR5 733 - The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds. | 2010-10-28 |
20100273806 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS - The present invention relates to certain (1,2,4-oxadiazol-3-yl)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl carboxylic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases. | 2010-10-28 |
20100273807 | Use of PDE III Inhibitors for the Treatment of Asymptomatic (Occult) Heart Failure - The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca | 2010-10-28 |
20100273808 | LACTATE SALT OF 4-[6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CAR- BOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS - This invention provides a compound of formula (I): | 2010-10-28 |
20100273809 | METHOD AND COMPOSITION FOR TREATING AN ALPHA ADRENOCEPTOR-MEDIATED CONDITION - Methods and compositions for the treatment of alpha-adrenoceptor mediated conditions. | 2010-10-28 |
20100273810 | METHOD OF TREATING COGNITIVE IMPAIRMENTS AND SCHIZOPHRENIAS - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 2010-10-28 |
20100273811 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpipera- zin-1-yl)benzamide and Salts Thereof - There is provided a compound of formula (I): | 2010-10-28 |
20100273812 | DIAZO BICYCLIC SMAC MIMETICS AND THE USES THEREOF - The invention relates to diazo bicyclic mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis. | 2010-10-28 |
20100273813 | NOVEL N-PHENYLACETAMIDE INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel N-phenylacetamide compounds of formula (I): | 2010-10-28 |
20100273814 | ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS - Disclosed herein is a compound of the formula wherein A and B are described herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed. | 2010-10-28 |
20100273815 | THIENO[2,3-D]-PYRIMIDIN-4(3H)-ONE COMPOUNDS WITH ANTIFUNGAL PROPERTIES AND PROCESS THEREOF - The present invention discloses novel compounds of the Formula (1), containing thieno-[2,3-d]pyrimidin-4(3H)-one moieties and pharmaceutically acceptable salts thereof, methods for preparing these compounds, the use of these compounds in prevention and treatment of fungal infections, and pharmaceutical preparations containing these novel compounds. | 2010-10-28 |
20100273816 | Quinazoline Compounds - Disclosed are quinazoline-based modulators of Liver X receptors (LXRs) and related methods. The modulators include compounds of formula (I): | 2010-10-28 |
20100273817 | Anti-cancer cyclopenta(g)quinazoline compounds - Cyclopenta[g]quinazolines of the formula (I):—wherein: A is a group OR or NR | 2010-10-28 |
20100273818 | INHIBITORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO - The present invention makes availables assays and reagents inhibiting paracrine and/or autocrine signals produced by a hedgehog protein or aberrant activation of a hedgehog signal transduction pathway, e.g., which involve the use of a steroidal alkaloid or other small molecule. | 2010-10-28 |
20100273819 | 3,3'-Spiroindolinone Derivatives - There are provided compounds of the formula | 2010-10-28 |
20100273821 | METHODS AND COMPOSITIONS FOR TREATING DRY EYE - This invention relates to treatment of dry eye. In particular, the invention relates to methods and formulations for treating dry eye based on topical application of opioid antagonists such as naltrexone. | 2010-10-28 |
20100273822 | Immediate release compositions and methods for delivering drug formulations using strong acid ion exchange resins - Solid oral dosage immediate release compositions comprising strong acid ion exchange resins and methods for delivering drug formulations. | 2010-10-28 |
20100273823 | Pesticide Composition Solution and Preparation Method Thereof - A pesticide composition solution is provided. The pesticide composition includes an effective amount of active ingredient according to the formula I and a pesticide adjuvant, | 2010-10-28 |
20100273824 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES - The present invention relates to compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer. | 2010-10-28 |
20100273825 | SOLID PHARMACEUTICAL COMPOSITION CONTAINING SOLIFENACIN AMORPHOUS FORM - The present invention relates to the provision of a stable solid pharmaceutical composition containing an amorphous form of solifenacin or a pharmaceutically acceptable salt thereof and capable of inhibiting decomposition accompanied by long-term storage, to provide the medical field with a formulation of solifenacin or a pharmaceutically acceptable salt thereof. More particularly, the present invention relates to a solid pharmaceutical composition, comprising an amorphous form of solifenacin or a pharmaceutically acceptable salt thereof, and one stabilizer for amorphous solifenacin or two or more stabilizers for amorphous solifenacin, selected from the group consisting of citric acid or a pharmaceutically acceptable salt (excluding a calcium salt) thereof, sodium pyrosulfite, and a pharmaceutically acceptable salt of ethylenediaminetetraacetic acid. | 2010-10-28 |
20100273826 | METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES - Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis. | 2010-10-28 |
20100273827 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1p) - The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders. | 2010-10-28 |
20100273828 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS - The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). R | 2010-10-28 |
20100273829 | Methods for Treating Disorders Associated with Hyperlipidemia in a Mammal - The invention is directed to methods for treating disorders associated with hyperlipidemia in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, BMS-201038 and implitapide) and a fibrate (for example, fenofibrate). Co-administration of the MTP inhibitor with the fibrate produces a therapeutic benefit, for example, a reduction in the concentration of cholesterol and/or triglycerides in the blood stream, but with fewer or reduced side effects than when higher dosages of the MTP inhibitor are used during monotherapy to provide the same or similar therapeutic benefit. | 2010-10-28 |
20100273830 | NOVEL INSECTICIDES - An insecticidal compound of formula (I) in which G | 2010-10-28 |
20100273831 | FLUORO ALKYL SUBSTITUTED BENZIMIDAZOLE CANNABINOID AGONISTS - The present invention is related to novel benzimidazole compounds of formula (I) having cannabinoid receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, in particular humans. | 2010-10-28 |
20100273832 | INSECTICIDAL COMPOUNDS - A compound of formula (I): wherein A | 2010-10-28 |
20100273833 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS - The invention relates to 2-sulfinyl- or 2-sulfonyl-substituted imidazole derivatives of the formula (I) in which the radicals R | 2010-10-28 |
20100273834 | TREATMENT OF ONYCHOMYCOSIS AND RELATED COMPOSITIONS INCLUDING UREA - The present invention generally relates to the treatment of onychomycosis. More specifically, it relates to combination therapies for the treatment of onychomycosis and related compositions. In a composition aspect, the present invention provides a composition for the treatment of onychomycosis, wherein the composition includes Ciclopirox and urea. In a method aspect, the present invention provides a method for treating onychomycosis in a patient suffering from the disease. The method involves topically administering a composition to at least one toe or fingernail of the patient and the composition includes Ciclopirox and urea. | 2010-10-28 |
20100273835 | NOVEL COMPOUNDS - The invention provides compounds of general formula (I) | 2010-10-28 |
20100273836 | OXIME ETHER DERIVATIVE AND FUNGICIDE FOR AGRICULTURAL AND HORTICULTURAL USE - The present invention provides a novel oxime ether derivative represented by the following formula (I), or salt thereof, that can be industrially produced advantageously, and can function as a fungicide for agricultural and horticultural use that has reliable effects and can be used safely, and a fungicide for agricultural and horticultural use that contains at least one of these compounds as an active ingredient thereof. In addition, the present invention provides a novel ketone derivative that is a production intermediate of the oxime ether derivative. | 2010-10-28 |
20100273837 | ANTIBACTERIAL AGENTS - Compounds of formula (IA) or (IB) have antibacterial activity: wherein W is ═CH— or ═N—; Ri and R2 are independently selected from hydrogen, fluoro and chloro, provided that Ri and R2 are not each hydrogen when W is ═CH—; n is 0 or 1; X is —O—, —S—, or —CH | 2010-10-28 |
20100273838 | STABLE TOPICAL COMPOSITIONS FOR 1,2,4-THIADIAZOLE DERIVATIVES - The present application provides a stable topical composition comprising a compound of 1,2,4-thiadiazole derivatives and the related thiourea derivatives. The stable topical composition may be present in various forms, including aqueous gel, cream, and emulsion. The stable topical composition may be stored at refrigerated or ambient condition for a reasonable shelf-life. The present application also provides a method of treating dermatologic disorders mediated by a melanocortin receptor using the stable topical composition. The stable composition may be delivered using a single chamber or dual chamber device. A method of preparing and delivering the stable composition is also provided. | 2010-10-28 |
20100273839 | Compounds Having Activity in Correcting Mutant-CFTR Processing and Uses Thereof - The invention provides compositions, pharmaceutical preparations and methods for increasing activity of a mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR). The compositions pharmaceutical preparations and methods are useful for the study and treatment of disorders associated with mutant-CFTR, such as cystic fibrosis. The compositions and pharmaceutical preparations of the invention may comprise one or more bithiazole-containing compounds of the invention, or an analog or derivative thereof. | 2010-10-28 |
20100273840 | WATER-SOLUBLE POLYMER-BASED CANTHARIMIDES AS POTENTIALLY SELECTIVE ANTI-TUMOR AGENTS - A cantharimide compound may include the backbone of formula (1). R | 2010-10-28 |
20100273841 | AMINE-DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF - This invention provides an anorectic or anti-obesity composition comprising a compound of the formula (I):
| 2010-10-28 |